Research Specifications
- Component 1:
- CJC-1295 No DAC (Mod GRF 1-29) — GHRH analogue
- Component 2:
- Semaglutide — GLP-1 receptor agonist
- Form:
- Lyophilized powder blend
- Purity:
- ≥98% each component (HPLC verified)
- Storage:
- −20°C long-term / 4°C up to 4 weeks reconstituted
- Reconstitution:
- Bacteriostatic water
GLP-1 C + GLP-1 S
Pre-blended CJC-1295 No DAC + Semaglutide combination — GH secretagogue paired with GLP-1 agonism in a single research preparation.
−14.9%
Semaglutide Weight Loss
STEP-1, 2.4mg, 68 weeks
Synergistic
GH + GLP-1 Body Recomp
Independent receptor pathways
$109.99
Combo Price
vs separate purchases
Receptor Targets
Dual Pathway: GH Axis + GLP-1 Receptor Agonism
This combination pairs CJC-1295 No DAC (a GHRH analogue stimulating pituitary GH release) with Semaglutide (a GLP-1 receptor agonist reducing appetite and improving glucose metabolism). The two compounds target entirely independent receptor systems — GHRH-R (pituitary) and GLP-1R (hypothalamus, pancreas, GI) — providing complementary anabolic and metabolic effects in a single preparation. The GH pulse from CJC-1295 stimulates IGF-1 production supporting lean mass, while Semaglutide drives fat loss via caloric restriction signaling.
Research Highlights
Body Recomposition Protocol Design
The GH axis (CJC-1295) and GLP-1 axis (Semaglutide) address body composition from complementary angles: GLP-1 drives a caloric deficit and fat mobilization; GH pulses stimulate IGF-1, protecting lean mass and supporting anabolic signaling in muscle tissue during caloric restriction. Together they target the fat loss + lean preservation phenotype central to body recomposition research.
Cost and Protocol Convenience
Pre-blending reduces the number of separate preparations and reconstitution steps in research protocols. For researchers investigating both GH secretagogue and GLP-1 agonist effects simultaneously, the combination provides a single preparation with both active compounds.
Comparison to Retatrutide Protocols
The GLP-1 C + GLP-1 S combo addresses similar research questions as the clavicular retatrutide stack but uses semaglutide (GLP-1 only) rather than retatrutide (triple agonist). It represents an intermediate protocol between GH secretagogue monotherapy and full triple-agonist protocols.
Research FAQ
What is GLP-1 C in this combination?
How does this compare to the CJC1295/Ipamorelin blend?
Is the $109.99 combo price competitive?
Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.
Price Comparison
| Supplier | Purity | Price | Shipping |
|---|---|---|---|
| Apollo (via ClavTides) | >98% HPLC | $109.99 | Free over $200 |
| Generic Research Suppliers | Varies (often <95%) | Similar–Higher | Varies |
| Pharmaceutical (Rx only) | Pharmaceutical grade | Not available for research | Rx required |
GLP-1 C + GLP-1 S
$109.99